Tetrahydrouridine (NDec)

Product Information

Scientific name: Tetrahydrouridine (NDec)
Brand name: N/A
RESPONSIBLE: Novo Nordisk

Clinical Trial/Study Information

Trial Name: ASCENT1
Code: NCT05405114
Phase: 2
Eligible patient diagnosis: SCD (adults) (age 18 and above)
No. of Patients enrolled: 96 [actual] (Last update: 27/03/2026)
Study Sites: 68 Sites per country

Anticipated completion date: July 2025
Scope of the Study / Aim: Efficacy and safety of once- or twice-weekly NDec to increase in HbF haemoglobin levels, reduce sickling and VOCs

Regulatory Information

Status: Not Authorised

Additional notable points:

• EMA: N/A
• FDA: N/A
• MHRA: N/A